TISSIUM, a privately-owned medtech company developing biomorphic programmable polymers for tissue reconstruction, has closed a Series C round of financing, raising €50 million from new and existing international investors. 

Cathay Health, affiliated to global investment firm Cathay Capital, led new investors and joined other institutional and individual backers while existing shareholders were led by Sofinnova Partners, a historical cornerstone investor, reinforcing TISSIUM shareholding structure. As part of the financing, Cathay Health co-founder and managing partner Hongjie Hu will be joining TISSIUM’s board of directors.

This latest funding round coincides with a period of rapid growth at TISSIUM that is expected to continue as it scales its operations and adds to its executive team. The financing will allow TISSIUM to continue to execute on its development plan, funding the company up to the commercialisation of its leading nerve repair, hernia repair and cardiovascular sealant products.

As TISSIUM adds to its platform with products in new therapeutic areas, it will continue to pursue international expansion, leveraging in-house production and manufacturing facilities, as well as entering partnerships in certain verticals.

Christophe Bancel, CEO of TISSIUM, said: “With the closing of our Series C financing round, TISSIUM is well-positioned to take the next steps to commercialisation. This funding significantly bolsters our ability to move with speed towards our goal of enhancing tissue reconstruction for patients. This financing will contribute significantly to TISSIUM’s ability to take advantage of the variety of opportunities we have to advance our innovation in this space.”

Antoine Papiernik, managing partner at Sofinnova Partners, said: “At Sofinnova Partners, we have been convinced since the beginning of TISSIUM’s potential to revolutionise tissue repair and bring a truly innovative solution for patients worldwide. We are pleased to be joined by Cathay Health and other investors who share this vision as we continue to support TISSIUM and provide the means for this exceptional team to pursue its development and prepare the commercialisation of its lead products.”

Hongjie Hu, co-founder and managing partner of Cathay Health, added: “TISSIUM is creating the future of tissue reconstruction on all continents. Its expandable platform is solving for widespread problems in surgeries addressing the needs of atraumatic repairs and can be applied to multiple, large, unmet therapeutic areas. As a cross-border investment platform spanning the US, Europe and Asia, we look forward to bringing the global outlook, resources and health ecosystem to support TISSIUM’s brilliant team in its international expansion and for the next steps toward commercialisation and growth.”